Prevention of Common Cancers of the Female Genital Tract

Chapter

Abstract

The world has seen incremental success in the outcomes of patients with cancer over the past 60 years. Ever-growing surgical expertise, improvements in radiation techniques, combination chemotherapy, supportive care, improved diagnostics, and more recently targeted therapy, all have led to a changed landscape. A significant number of cancer patients, previously deemed incurable are now cured. What cannot be cured does not have to be endured. Several incurable cancers are now managed like chronic disease. However, despite the success in treatment of cancer, total number of patients who die as a result of cancer continue to increase, and this is a direct reflection of the rising incidence. According to the Globocan, 12.7 million patients were diagnosed with cancer in 2008, and the number is likely to increase almost twofold to 22.2 million by 2030. Similarly, 7.6 million people died of cancer in 2008, and the number is likely to increase to 17 million by 2030. Despite all the excitement and success in accurate diagnosis and refined treatment of cancer, clearly a lot more needs to be achieved in research and implementation of effective policies to reduce the incidence of cancer, in order to decrease the overall burden of the disease and the attendant mortality. Cancer should be treated across the continuum, if meaningful gain in survival is the goal. In this chapter, developments in the field of prevention of gynecological cancers are reviewed.

References

  1. 1.
    Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.1, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2014. Available from: http://globocan.iarc.fr. Accessed 16 January 2015.Google Scholar
  2. 2.
    Romaguera D, Vergnaud AC, Peeters PH, van Gils CH, Chan DS, Ferrari P, et al. Is concordance with World Cancer Research Fund/American Institute for Cancer Research guidelines for cancer prevention related to subsequent risk of cancer? Results from the EPIC study. Am J Clin Nutr. 2012;96:150–63.CrossRefPubMedGoogle Scholar
  3. 3.
    Vergnaud AC, Romaguera D, Peeters PH, van Gils CH, Chan DS, Romieu I, et al. Adherence to the World Cancer Research Fund/American Institute for Cancer Research guidelines and risk of death in Europe: results from the European Prospective Investigation into Nutrition and Cancer cohort study1,4. Am J Clin Nutr. 2013;97:1107–20.CrossRefPubMedGoogle Scholar
  4. 4.
    Hastert TA, Beresford SA, Patterson RE, Kristal AR, White E. Adherence to WCRF/AICR cancer prevention recommendations and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2013;22:1498–508.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Walter RB, Buckley SA, White E. Regular recreational physical activity and risk of hematologic malignancies: Results from the prospective vitamins and lifestyle (VITAL) study. Ann Oncol. 2013;24:1370–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Sueblinvong T, Carney ME. Current understanding of risk factors for ovarian cancer. Curr Treat Options in Oncol. 2009;10:67–81.CrossRefGoogle Scholar
  7. 7.
    Hartmann LC, Lindor NM. The role of risk-reducing surgery in hereditary breast and ovarian cancer. N Eng J Med. 2016;374:454–68.CrossRefGoogle Scholar
  8. 8.
    Toss C, Tomasello E, Razzaboni G, et al. Hereditary ovarian cancer: not only BRCA 1 and 2 genes. BioMed Res Int. 2015:341–8.Google Scholar
  9. 9.
    Foong KW, Bolton H. Obestiy and ovarian cancer risk: a systematic review. Post Reprod Health. 2017;23(4):183–98.  https://doi.org/10.1177/2053369117709225.CrossRefPubMedGoogle Scholar
  10. 10.
    Crane TE, Khulpateea BR, Alberts DS, et al. Dietary intake and ovarian cancer risk: a systematic review. Cancer Epidemiol Biomark Prev. 2014;23(2):255–73.CrossRefGoogle Scholar
  11. 11.
    Dolecek TA, McCarthy BJ, Joslin CE, et al. Prediagnosis food patterns are associated with length of survival from epithelial ovarian cancer. J Am Diet Assoc. 2010;110(3):369–82.CrossRefPubMedGoogle Scholar
  12. 12.
    Thomson CA, Crane E, Wertheim BC, et al. Diet quality and survival after ovarian cancer: results from the Women’s Health Initiative. J Natl Cancer Inst. 2014;106(11):pii: dju314.CrossRefGoogle Scholar
  13. 13.
    Zhou Y, Chlebowski R, LaMonte MJ, et al. Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: Results from the Women's Health Initiative. Gynecol Oncol. 2014;133(1):4–10.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Thomson CA, Crane TE, Miller A, et al. A randomized trial of diet and physical activity in women treated for stage II–IV ovarian cancer: rationale and design of the Lifestyle Intervention for Ovarian Cancer Enhanced Survival (LIVES): an NRG Oncology/Gynecologic Oncology Group (GOG-225) Study. Contemp Clin Trials. 2016;49:181–9.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
  16. 16.
  17. 17.
    Moyer VA, U.S. Preventive Services Task Force. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2012;157(12):900–4.  https://doi.org/10.7326/0003-4819-157-11-201212040-00539.CrossRefPubMedGoogle Scholar
  18. 18.
    Menon U, McGuire AJ, Raikou M, et al. The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Br J Cancer. 2017 Aug 22;117(5):619–27.  https://doi.org/10.1038/bjc.2017.222.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Tewari KS, Monk BJ. The 21st century handbook of clinical ovarian cancer. Switzerland: Springer International Publishing; 2015.  https://doi.org/10.1007/978-3-319-08066-6_2.CrossRefGoogle Scholar
  20. 20.
    Paluch-Shimon S, Cardoso F, Sessa C, et al. on behalf of the ESMO Guidelines Committee. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening Ann of Oncol 27 (Suppl 5): v103–v110, 2016 doi: https://doi.org/10.1093/annonc/mdw327.
  21. 21.
    Olopade OI, Artioli G. Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J. 2004;10(Suppl 1):S5–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol. 2011;22(Suppl 6):vi35–9.PubMedGoogle Scholar
  23. 23.
    Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Radiother Oncol. 2015;117(3):559–81.  https://doi.org/10.1016/j.radonc.2015.11.013.CrossRefPubMedGoogle Scholar
  24. 24.
  25. 25.
    Anderson AS, Key TJ, Norat T, et al. European code against cancer 4th Edition: obesity, body fatness and cancer. Cancer Epidemiol. 2015;39(Suppl 1):S34–45.  https://doi.org/10.1016/j.canep.2015.01.017.CrossRefPubMedGoogle Scholar
  26. 26.
    Welti LM, Beavers DP, Caan BJ, et al. Weight fluctuation and cancer risk in post-menopausal women: The women’s health initiative. Cancer Epidemiol Biomarkers Prev. 2017;26(5):779–86. pii: cebp.0611.2016.CrossRefPubMedGoogle Scholar
  27. 27.
    Nagle CM, Marquart L, Bain CJ, et al. Australian National Endometrial Cancer Study Group. Impact of weight change and weight cycling on risk of different subtypes of endometrial cancer. Eur J Cancer. 2013;12:2717–26.CrossRefGoogle Scholar
  28. 28.
    Luo J, Chlebowski RT, Hendryx M, et al. Intentional weight loss and endometrial cancer risk. J Clin Oncol. 2017;35(11):1189–93.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Parker ED, Folsom AR. Intentional weight loss and incidence of obesity-related cancers: the Iowa Women’s Health Study. Int J Obes Relat Metab Disord. 2003;27(12):1447–52.CrossRefPubMedGoogle Scholar
  30. 30.
    Campagnoli C, Abbà C, Ambroggio S, et al. Life-style and metformin for the prevention of endometrial pathology in postmenopausal women. Gynecol Endocrinol. 2013;29(2):119–24.CrossRefPubMedGoogle Scholar
  31. 31.
    Ward KK, Roncancio AM, Shah NR, et al. Bariatric surgery decreases the risk of uterine malignancy. Gynecol Oncol. 2014;133(1):63–6.  https://doi.org/10.1016/j.ygyno.2013.11.012.CrossRefPubMedGoogle Scholar
  32. 32.
    Anveden Å, Taube M, Peltonen M, et al. Long-term incidence of female-specific cancer after bariatric surgery or usual care in the Swedish Obese Subjects Study. Gynecol Oncol. 2017;145(2):224–9.  https://doi.org/10.1016/j.ygyno.2017.02.036.CrossRefPubMedGoogle Scholar
  33. 33.
  34. 34.
    Jeronimo J, Castle PE, Temin S, et al. Secondary prevention of cervical cancer: ASCO resource-stratified clinical practice guideline. J Global Oncol. 2017;3(5):635–57.  https://doi.org/10.1200/JGO.2016.006577.CrossRefGoogle Scholar
  35. 35.
    Arrossi S, Temin S, Garland S, et al. Primary prevention of cervical cancer. ASCO. First Global Guidance for HPV Vaccination for Cervical Cancer Prevention. ASCO’s website. Mar. 17, 2017. doi:  https://doi.org/10.1200/JGO.2016.008151.
  36. 36.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of MedicineSultan Qaboos University Hospital, Sultan Qaboos UniversityMuscatOman

Personalised recommendations